Ignite Creation Date:
2024-05-06 @ 7:54 PM
Last Modification Date:
2024-10-26 @ 3:16 PM
Study NCT ID:
NCT06173076
Status:
RECRUITING
Last Update Posted:
2023-12-15
First Post:
2023-11-14
Brief Title:
A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis
Sponsor:
Second Affiliated Hospital School of Medicine Zhejiang University
Organization:
Second Affiliated Hospital School of Medicine Zhejiang University
Study Overview
Official Title:
A Prospective Study to Evaluate Clinical Outcomes in Patients With Anti-leucine-rich Glioma-inactivated 1 Encephalitis
Status:
RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Anti-leucine-rich glioma-inactivated 1 LGI1 encephalitis has been increasingly identified as the second most common type of autoimmune encephalitis after anti-N-methyl-D-aspartate receptor NMDAR encephalitis It presents with acute or subacute onset of epileptic seizures anterograde amnesia behavior disturbances sleep disorders and hyponatremia In most patients with anti-LGI1 encephalitis immunotherapy is successful in treating the encephalitis However relapses chronic epilepsy cognitive declines and psychiatric problems have been reported in some cases
So far prospective studies to evaluate its clinical outcomes still remain limited In this project the investigators will use clinical features and advanced paraclinical examinations to prospectively investigate the clinical outcomes and the associated factors in patients with anti-LGI1 encephalitis
So far prospective studies to evaluate its clinical outcomes still remain limited In this project the investigators will use clinical features and advanced paraclinical examinations to prospectively investigate the clinical outcomes and the associated factors in patients with anti-LGI1 encephalitis
Detailed Description:
In this prospective study the investigators are aiming to recruit newly diagnosed patients with anti-LGI1 encephalitis At the acute stage and during the follow-up some routine and advanced paraclinical examinations will be conducted including dynamic blood andor cerebrospinal fluid CSF test multimodal brain magnetic resonance imaging MRI including functional MRI diffusion tensor imaging arterial spin labeling et al Electroencephalography EEG or continuous video-EEG VEEG positron emission tomography PET neuropsychological tests and some other paraclinical examinations Through the comprehensive analysis the clinical outcomes and associated factors are further explored in anti-LGI1 encephalitis
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None